Table 1. Characterization of the T1D patients.

Patient	Sex	Age, years	Duration of T1D, weeks	Medication*	ICA	GAD	IA-2
1	M	32	<1	No	Pos	Pos	Pos
2	F	32	12	No	Neg	Pos	Neg
3	F	31	<1	No	Pos	Pos	Pos
4	F	23	<1	No	Pos	Neg	ND
5	M	19	<1	No	Neg	Neg	Pos
6	F	35	<1	No	Pos	Pos	Pos
7	F	33	28	No	Pos	Pos	ND

F, female; M, male. The presence (Pos), absence (Neg), or no data available (ND) of antibodies to islet cells (ICA), glutamic acid decarboxylase (GAD), and tyrosine phosphatase IA2 (IA-2) are marked. Healthy blood donors, all negative for ICA, GAD, and IA-2, served as sources of control sera.

^*Insulin was the only medication administered